Raghav Kapoor – Be on High Alert When You’re Doing Well

<p><strong>BIO: </strong>Raghav Kapoor is the CEO and Co-Founder of Smartkarma, an Asia-focused Investment Research Network that serves global institutional investors, corporates, and private wealth.</p><p><strong>STORY: </strong>Raghav invested 2% of his portfolio in a biotech company in the US simply because it was run by people he believed had a good reputation. He ended up losing 98% of his investment.</p><p><strong>LEARNING: </strong>Invest within your area of competence or expertise. Capital preservation and compounding are essential. Great people get it wrong too.</p><p>&nbsp;</p><blockquote class="ql-align-center"><strong>“I try to get in early on an investment that I know is so simple that I can explain it in one sentence, and almost everyone would agree to it.”</strong></blockquote><blockquote class="ql-align-center">Raghav Kapoor</blockquote><p>&nbsp;</p><h2>Guest profile</h2><p><a href="https://www.linkedin.com/in/ragkap/" rel="noopener noreferrer" target="_blank"><strong>Raghav Kapoor</strong></a> is the CEO and Co-Founder of <a href="https://www.smartkarma.com/home/" rel="noopener noreferrer" target="_blank">Smartkarma</a>, an Asia-focused Investment Research Network that serves global institutional investors, corporates, and private wealth.</p><p><a href="https://www.smartkarma.com/home/smartkarma-plus-welcome-offer/?promo=welcome199&amp;utm_source=sendgrid.com&amp;utm_medium=email&amp;utm_campaign=website" rel="noopener noreferrer" target="_blank">Subscribe to Smartkarma Plus</a> - Institutional Level Investment Insight for the Aspirational Investor at a special welcome offer of just $1.99 for the first month.</p><h2>Worst investment ever</h2><p>In 2021, Raghav had an excellent portfolio performance behind him. He got overzealous and invested in a US biotech company. There were a lot of things that looked really great about this company. For starters, the company had been operational for about 15 years. They were developing a new platform for cancer research and drugs, and the specific type of can